University College London

Trace Neuroscience emerged from an effort to create a new start-up using genomic insights to discover and develop treatments for amyotrophic lateral sclerosis (ALS). The company’s founders focused on

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a

Eisai Co., Ltd. has a challenging task ahead in bringing its Biogen, Inc. -partnered amyloid protofibril-clearing antibody Leqembi (lecanemab) to Alzheimer’s patients in a market that is struggling

Amylyx Hopes Sunnybrook Might Discover New Methods For Fighting ALS Although it is in the midst of a protracted effort to obtain US Food and Drug Administration approval for its investigational mitoch